Needham & Company Assumes Neurocrine Bio. (NBIX) at Hold
Tweet Send to a Friend
Needham & Company analyst Ami Fadia assumes coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Hold rating.The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE